Invited Speaker
37th TROG Cancer Research Annual Scientific Meeting 2025
Days
Tuesday, 18th March
Wednesday, 19th March
Thursday, 20th March
Friday, 21st March
Search
Speakers
Durvalumab after high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer. DAHRTS – a randomized phase III trial
(#41)
Bjørn Grønberg
1
Norwegian University of Science and Technology, Torgarden, Norway
Content is not available at the time of publishing.